REGENXBIO Inc.

NASDAQ:RGNX

Biotechnology

Healthcare
$7.26 +1.97%

+$0.16 today

Market cap
$480.05M
Beta
1.03
P/E (TTM)
-1.5
EPS (TTM)
-$5.53
52W Low $5.46High $16.19

Volume 0.70M

Average 1.24M

RGNX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

REGENXBIO Inc.NASDAQ: RGNX

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q1 FY2026 weighted avg shares (diluted) of 52.43M shares rose 1.9% year over year, in line with the +1.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 1.3% from the prior quarter. Over 3 fiscal years it compounded at +6.1% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1.9% holds above the trailing-twelve-month pace of +1.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
52.43M+1.3% QoQ
Last fiscal yearDec 2025
51.57M+4.2% YoY
LTMMar 2026
51.84M+1.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.9%——
1 year+4.2%——
3-year CAGR+6.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
51.57M USD
Year-over-year change
+4.2%
4-year CAGR
+4.1%

Weighted Avg Shares (Diluted) vs competitors

How RGNX compares with its peers on the latest reported figures

  • RGNX's LTM Mar 2026 weighted avg shares (diluted) of 51.84M shares is the lowest of the 10 companies compared; the peer median is 80.99M shares.
  • Its year-over-year change of +1.8% is the 9th highest of 10, against a peer median of +13.7%.
  • Over three fiscal years its annual growth of +6.1% compares with a peer median of +17.7%.
RGNX Competitors Peer median
Weighted Avg Shares (Diluted) for RGNX and competitors
Company Period LTM YoY 3-year CAGR
PGENPrecigen, Inc.LTM Jun 2026334.02M +15.3%+15.0%
OCGNOcugen, Inc.LTM Mar 2026307.2M +9.9%+11.8%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
SLDBSolid Biosciences Inc.LTM Mar 202698.28M +94.3%+117.4%
MGTXMeiraGTx Holdings plcLTM Mar 202680.99M +13.7%+21.2%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 202665.52M +98.2%+28.7%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 202659.51M +7.9%+21.4%
VYGRVoyager Therapeutics, Inc.LTM Mar 202658.91M +1.6%+15.2%
QUREuniQure N.V.LTM Mar 202658.39M +17.2%+7.2%
RGNXREGENXBIO Inc.LTM Mar 202651.84M +1.8%+6.1%
Peer median (excluding RGNX) 80.99M+13.7%+17.7%

Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue470.35M112.72M90.24M83.33M170.44M
Cost of Revenue51.83M54.55M37.21M33.57M20.3M
Gross Profit418.51M58.18M53.03M49.76M150.14M
Gross Margin89.0%51.6%58.8%59.7%88.1%
Research & Development181.44M242.45M232.27M208.52M228.3M
Selling, General & Admin79.33M85.28M88.49M76.62M82.86M
Operating Expenses258.53M321.06M321.16M283.11M311.34M
Depreciation & Amortization9.56M12.91M17.32M16.22M15.62M
EBITDA177.09M(244.24M)(239.46M)(198.23M)(133.26M)
EBITDA Margin37.7%-216.7%-265.4%-237.9%-78.2%
Operating Income159.98M(262.88M)(268.13M)(233.35M)(161.2M)
Operating Margin34.0%-233.2%-297.1%-280.0%-94.6%
Interest Income719K342K25K174K12.27M
Interest Expense26.28M23.25M6.86M12.66M45.01M
Other Income / Expenses(18.73M)(17.53M)4.48M6.24M(32.68M)
Income Before Tax141.25M(280.41M)(263.65M)(227.1M)(193.88M)
Pre-Tax Margin30.0%-248.8%-292.2%-272.5%-113.8%
Income Tax Expense13.41M(84K)(152K)00
Net Income127.84M(280.32M)(263.49M)(227.1M)(193.88M)
Net Margin27.2%-248.7%-292.0%-272.5%-113.8%
EPS (Basic)3.01(6.50)(6.02)(4.59)(3.76)
EPS (Diluted)2.91(6.50)(6.02)(4.59)(3.76)
Weighted Avg Shares42.44M43.15M43.73M49.51M51.57M
Weighted Avg Shares (Diluted)43.91M43.15M43.73M49.51M51.57M

REGENXBIO Inc.

NASDAQ:RGNX

Intrinsic Alpha fair value

Locked

Current Price

$7.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.